* Zymeworks Inc reported a quarterly adjusted loss of 39 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of seven analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -75 cents to -14 cents per share.

* Revenue fell 3.1% to $16.00 million from a year ago; analysts expected $15.30 million.

* Zymeworks Inc's reported EPS for the quarter was a loss of 39 cents​.

* The company reported a quarterly loss of $29.85 million.

* Zymeworks Inc shares had risen by 10.5% this quarter and gained 33.5% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 14.5% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Zymeworks Inc is 14.00 This summary was machine generated from LSEG data November 1 at 03:35 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.40 -0.39 Beat

Jun. 30 2024 -0.32 -0.27 Beat

Mar. 31 2024 -0.29 -0.42 Missed

Dec. 31 2023 -0.43 -0.20 Beat